Results 21 to 30 of about 1,264,680 (377)

Progression from ocular hypertension to visual field loss in the English hospital eye service [PDF]

, 2020
Background There are more than one million National Health Service visits in England and Wales each year for patients with glaucoma or ocular hypertension (OHT).
Azuara-Blanco, A., Bryan, S. R., Crabb, D. P., Kelly, S. R., Khawaja, A. P., Sparrow, J. M.   +5 more
core   +2 more sources

Relationship between blood pressure and intraocular pressure in the JPHC-NEXT eye study

Scientific Reports, 2022
Although a positive link between hypertension and intraocular pressure (IOP) has been suggested, the individual effects of systolic and diastolic blood pressure (SBP and DBP, respectively) on IOP remain unclear, particularly among Japanese populations ...
Tomoyo Yasukawa, Akiko Hanyuda, Kazumasa Yamagishi, Kenya Yuki, Miki Uchino, Yoko Ozawa, Mariko Sasaki, Kazuo Tsubota, Norie Sawada, Kazuno Negishi, Shoichiro Tsugane, Hiroyasu Iso   +11 more
doaj   +1 more source

Intraocular Pressure Fluctuation: Is It Important? [PDF]

, 2018
Elevated intraocular pressure (IOP) is a major risk factor for the development and progression of glaucoma. Previous prospective, randomized, long-term studies have demonstrated the strength of IOP reduction in slowing the progression of disease.
Caprioli, Joseph, Kim, Ji Hyun
core   +5 more sources

The Application of Nitric Oxide for Ocular Hypertension Treatment

Molecules, 2021
Despite of various therapeutic methods for treating ocular hypertension and glaucoma, it still remains the leading cause of irreversible blindness. Intraocular pressure (IOP) lowering is the most effective way to slow disease progression and prevent ...
Binze Han, Maomao Song, Liping Li, Xinghuai Sun, Yuan Lei   +4 more
doaj   +1 more source

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review [PDF]

, 2017
The acute and chronic effects of repeated intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure have not been fully characterized, and the development of sustained ocular hypertension could adversely affect ...
Bracha, Peter, Cantor, Louis B., Ciulla, Thomas A., Moore, Nicholas A., WuDunn, Darrell   +4 more
core   +1 more source

Delaying Treatment of Ocular Hypertension [PDF]

Archives of Ophthalmology, 2010
To compare the safety and efficacy of earlier vs later treatment in preventing primary open-angle glaucoma (POAG) in individuals with ocular hypertension.One thousand six hundred thirty-six individuals with intraocular pressure (IOP) from 24 to 32 mm Hg in 1 eye and 21 to 32 mm Hg in the fellow eye were randomized to observation or to topical ocular ...
Michael A, Kass, Mae O, Gordon, Feng, Gao, Dale K, Heuer, Eve J, Higginbotham, Chris A, Johnson, John K, Keltner, J Philip, Miller, Richard K, Parrish, M Roy, Wilson   +9 more
openaire   +2 more sources

Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema

Journal of the Formosan Medical Association, 2017
To analyze the prognostic factors for ocular hypertension after posterior subtenon injection of triamcinolone acetonide (PSTA) for the treatment of diabetic macular edema (DME).
Yi-Ting Hsieh, Chung-May Yang, Shu-Hui Chang   +2 more
doaj   +1 more source

Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension

Journal of glaucoma, 2020
Supplemental Digital Content is available in the text. Precis: In pooled phase III analyses, once-daily netarsudil 0.02% resulted in intraocular pressure (IOP) reduction that was noninferior to twice-daily timolol 0.5%, with minimal treatment-related ...
I. Singh, R. Fechtner, J. Myers, Terry Kim, D. Usner, Hayley McKee, Huan Sheng, R. Lewis, T. Heah, C. Kopczynski   +9 more
semanticscholar   +1 more source

Glycocalyx Degradation in Retinal and Choroidal Capillary Endothelium in Rats with Diabetes and Hypertension [PDF]

, 2010
Endothelial glycocalyx (GCX) has been reported as a protective factor for vascular endothelial cells (VEC) in diabetes and hypertension. However, the involvement of GCX impairment in ocular vasculopathy remains unclear.
Kumase, Fumiaki, Mohri, Satoshi, Morizane, Yuki, Ohtsuka, Aiji, Ohtsuki, Hiroshi, Takasu, Ippei   +5 more
core   +1 more source

Neuronal Epac1 mediates retinal neurodegeneration in mouse models of ocular hypertension

Journal of Experimental Medicine, 2020
This study shows that the cAMP/Epac1 pathway plays a critical role in retinal neurodegeneration via CaMKII activation in mouse models of ocular hypertension and suggests that Epac1 is a therapeutic target for neuroprotection in glaucoma.
Wei Liu, Yonju Ha, Fan Xia, Shuang Zhu, Yi Li, Shuizhen Shi, Fang C. Mei, K. Merkley, G. Vizzeri, M. Motamedi, Xiaodong Cheng, Hua Liu, Wenbo Zhang   +12 more
semanticscholar   +1 more source